Axogen Seeks FDA Approval For Avance Nerve Graft
Executive Summary
Supported by results from the RECON trial, the Florida company will file a biologics license application for its Avance nerve graft used surgical repair of finger injuries
You may also be interested in...
AxoGen Creates New Chief Commercial Officer Role
Axogen has hired Boston Scientific alumnus Jon Gingrich to the newly created role of chief commercial officer (CCO). Gingrich will oversee development and execution of the company's sales and marketing development as it expands its portfolio of nerve regeneration products.
Axogen Finds Permanent CFO
AxoGen Inc., which develops peripheral nerve injury surgical solutions, appointed Peter Mariani CFO, effective March 1. Mariani replaces Greg Freitag, who has served as interim CFO since August 2015. Freitag will continue as general counsel, senior VP of business development, and as a member of the board of directors. Prior to joining the company, Mariani served as CFO of LensAR Inc., a privately held maker of next-generation femtosecond laser technology for refractive cataract surgery. He also served as CFO at Hansen Medical Inc., which designs and manufactures medical robotics for positioning and control of catheter-based technologies.
AxoGen: Advancing Regenerative Peripheral Nerve Repair
AxoGen, with three commercially available peripheral nerve repair products, is looking to expand its horizons into new clinical areas and improve quality of life for patients with challenging nerve damage.